Literature DB >> 7398736

Clinical pharmacokinetics of alcuronium chloride in man.

J Walker, C A Shanks, E J Triggs.   

Abstract

The pharmacokinetic behaviour of alcuronium is described for nineteen patients undergoing anaesthesia for elective surgery. Eleven patients received a single bolus intravenous dose of 0.25 mg/kg, while 8 patients required additional doses of 0.125 mg/kg. A two-compartment open model was found to describe adequately both the single dose and multiple dose data for the majority of patients. No significant differences were found in the model-independent pharmacokinetic parameters between the single and multiple dose studies. Mean values for the pooled data for the half-life (t 1/2 beta), apparent volume of distribution (Vd beta), volume of distribution at steady-state (Vdss), volume of the central compartment (Vc) and plasma clearance (Clp) were 198.75 min, 24.261, 20.891, 8.181 and 90.22 ml/min respectively. Evoked muscle twitch response was monitored in 17 of the patients to assess the degree of relaxant blockade. The bolus dose of alcuronium produced complete block in 9 patients and between 95 and 99% block in the remainder. The time of onset to maximum block ranged from 3 to 30 min with the concurrently measured plasma levels of alcuronium being 0.79 to 2.25 microgram/ml. The time taken following bolus administration to 5% recovery (95% paralysis) was a mean of 42 min and the corresponding mean alcuronium plasma concentration was 0.78 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398736     DOI: 10.1007/bf00570163

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetics and dynamics of muscle relaxants.

Authors:  D R Stanski; L B Sheiner
Journal:  Anesthesiology       Date:  1979-08       Impact factor: 7.892

4.  The fate of pancuronium bromide in man.

Authors:  S Agoston; G A Vermeer; U W Kertsten; D K Meijer
Journal:  Acta Anaesthesiol Scand       Date:  1973       Impact factor: 2.105

5.  [Pharmacokinetics of diallyl-nor-toxiferine in man].

Authors:  J Raaflaub; P Frey
Journal:  Arzneimittelforschung       Date:  1972-01

6.  Durations of action of d-tubocurarine and gallamine.

Authors:  L F Walts; J B Dillon
Journal:  Anesthesiology       Date:  1968 May-Jun       Impact factor: 7.892

7.  Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses.

Authors:  M I Ramzan; E J Triggs; C A Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

8.  Clinical pharmacokinetics of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

9.  Diallyl-nortoxiferine ("alloferin"): a clinical appraisal.

Authors:  B E Dwyer; B W Gunner; W D Walker
Journal:  Aust N Z J Surg       Date:  1967-08-01

10.  [Long-lasting neuromuscular effects of non-depolarizing muscle relaxants, as measured by tetanic stimulation (author's transl)].

Authors:  L Barth; R Dannhorn
Journal:  Anaesthesist       Date:  1977-03       Impact factor: 1.041

View more
  5 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 3.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

5.  Alcuronium kinetics in patients undergoing cardiopulmonary bypass surgery.

Authors:  J S Walker; K F Brown; C A Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.